September 11, 2008
According to Cutting Edge Information’s Research, Tyrosine Kinase Inhibitors to Generate Five Blockbusters By 2013
According to a new study by Cutting Edge Information, tyrosine kinase inhibitors may have five oncology drugs with annual sales over $1 billion by 2013.
This list of blockbuster oncology drugs includes Novartis' Gleevec. Annual sales of Gleevec are projected to steadily grow to $4.6 billion dollars in 2012, making it a top five oncology drug. There are four other approved tyrosine kinase inhibitors that are estimated to surpass $1 billion in annual sales by 2013, one of which is Pfizer's Sutent, which treats renal cell carcinoma.
"Tyrosine kinase inhibitors have proven themselves as effective treatments for many types of cancer," said Eric Bolesh, research manager at Cutting Edge Information. "That is one of the reasons pharma companies continue to invest heavily in new drugs within this class of oncology treatments. We will see many more treatments coming out of this class over the next few years."
The pipeline of upcoming tyrosine kinase inhibitors is quite robust. Major drug companies like Pfizer, Wyeth, Sanofi-Aventis, GlaxoSmithKline, AstraZeneca and Amgen all have drugs from this class in Phase III development. It is this promising pipeline, combined with the commercial success that has characterized existing drugs in this class, that lead analysts to estimate a $17 billion market for tyrosine kinase inhibitors by 2013. In terms of sales within the oncology space, tyrosine kinase inhibitors are second only to monoclonal antibodies.
The 420+ page study examines 17 monoclonal antibodies and more than 120 other drugs, and provides the following market analysis:
-- Individual Drug Profiles -- Drug profiles include information about drugs' competitive, strategic and market growth positions. -- Oncology Indication Market Outlook -- Detailed outlooks for the breast, colorectal, lung and prostate cancer and leukemia markets. -- Company Profiles -- Oncology breakdowns for companies that either have established oncology franchises or exciting development pipelines for new cancer compounds.
CONTACT INFORMATION: Eric Bolesh Email Contact 919-433-0209
SOURCE: Cutting Edge Information